Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Anlotinib Combined With Pemetrexed and Cisplatin in First Treatment for Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Negative Mutations

NCT03671538 is registered in ClinicalTrials.gov with Lingyu Luo as lead sponsor.

NCT NCT03671538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03671538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Anlotinib Combined With Pemetrexed and Cisplatin in First Treatment for Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Negative Mutations
Lead sponsor
Lingyu Luo
Phase
Not applicable
Overall status
Unknown status
Start date
October 1, 2018
Completion date
August 31, 2020
Enrollment
62 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer